Literature DB >> 16923090

Intravenous glucose-insulin-potassium during off-pump coronary artery bypass surgery does not reduce myocardial injury.

Y H Shim1, T D Kweon, J H Lee, S B Nam, Y L Kwak.   

Abstract

BACKGROUND: This randomized, double-blind, placebo-controlled study was designed to determine whether an intra-operative, intravenous infusion of glucose-insulin-potassium (GIK) could be helpful in the prevention of myocardial ischemia and in the maintenance of intra-operative cardiac performance in patients undergoing off-pump coronary artery bypass (OP-CAB) surgery.
METHODS: Eighty two adults undergoing elective OP-CAB surgery were randomly divided into two groups that received intravenously either 5% dextrose in water or GIK (50% dextrose in 500 ml of water; regular insulin, 125 IU; potassium, 80 mmol) at 0.75 ml/kg/h immediately before the induction of anesthesia to the end of surgery. To evaluate myocardial damage, creatine kinase MB and troponin T were measured before surgery, immediately after arrival in the intensive care unit and on the first post-operative day. To assess cardiac performance, hemodynamic data were obtained before and after the induction of anesthesia, before and after the bypass graft and after sternal closure. Blood glucose was measured at the same time.
RESULTS: There was no significant difference in cardiac enzymes, hemodynamic parameters and blood glucose between the two groups. The use of vasoactive, inotropic and/or anti-arrhythmic agents, insulin and supplemental glucose was not significantly different between the groups.
CONCLUSION: The results suggest that the intravenous administration of GIK during OP-CAB surgery neither reduces myocardial damage nor improves intra-operative cardiac performance in patients without contractile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923090     DOI: 10.1111/j.1399-6576.2006.01115.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

1.  Hyperinsulinemic Normoglycemia during Cardiac Surgery Reduces a Composite of 30-day Mortality and Serious In-hospital Complications: A Randomized Clinical Trial.

Authors:  Andra E Duncan; Daniel I Sessler; Hiroaki Sato; Tamaki Sato; Keisuke Nakazawa; George Carvalho; Roupen Hatzakorzian; Takumi Codere-Maruyama; Alaa Abd-Elsayed; Somnath Bose; Tamer Said; Maria Mendoza-Cuartas; Hyndhavi Chowdary; Edward J Mascha; Dongsheng Yang; A Marc Gillinov; Thomas Schricker
Journal:  Anesthesiology       Date:  2018-06       Impact factor: 7.892

2.  Hyperinsulinemic Normoglycemia Does Not Meaningfully Improve Myocardial Performance during Cardiac Surgery: A Randomized Trial.

Authors:  Andra E Duncan; Babak Kateby Kashy; Sheryar Sarwar; Akhil Singh; Olga Stenina-Adognravi; Steffen Christoffersen; Andrej Alfirevic; Shiva Sale; Dongsheng Yang; James D Thomas; Marc Gillinov; Daniel I Sessler
Journal:  Anesthesiology       Date:  2015-08       Impact factor: 7.892

3.  American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.

Authors:  Etie S Moghissi; Mary T Korytkowski; Monica DiNardo; Daniel Einhorn; Richard Hellman; Irl B Hirsch; Silvio E Inzucchi; Faramarz Ismail-Beigi; M Sue Kirkman; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2009-05-08       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.